Abzyme Therapeutics LLC
Pottstown, PA
- UEI
- H2MLEFWV36N6
- CAGE
- 62ES6
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 321 Jones Blvd #300, Pottstown, PA 19464, USA
- Website
- abzymetx.com
- Founded
- 2010
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Novel immune-escape uricase for treatment of hyperuricemia - abstract. High serum urate levels (hyperuricemia) and… | National Institute of Allergy and Infectious Diseases | $299,999 | |
| Brain-cell penetrating antibodies for treatment of progressive multiple sclerosis - abstract. Central nervous system… | National Institute of Neurological Disorders and Stroke | $1,197,321 | |
| Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases - abstract. Retinal… | National Eye Institute | $3,315,988 | |
| Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases | National Eye Institute | $299,989 | |
| Pemphigus-specific t cell engagers for pemphigus targeted immunotherapy | National Institute of Allergy and Infectious Diseases | $280,352 |
About Abzyme Therapeutics LLC
Abzyme Therapeutics LLC is a biopharmaceutical company that develops modular antibody fragments for immunotherapy. Through federal contracts, the company has provided research and development services related to enhancing HIV gp120 protein production using camelid VHH antibodies. This was funded by the NIH's National Institute of Allergy and Infectious Diseases as a Small Business Innovation Research program Phase I contract.
Abzyme Therapeutics LLC has received multiple federal grants to develop novel therapeutics. This includes an NIH National Institute of Neurological Disorders and Stroke grant to engineer brain-penetrating bispecific antibodies to inhibit complement activation and stimulate nerve growth for treating progressive multiple sclerosis. Additionally, Abzyme Therapeutics LLC has received NIH National Eye Institute and NIH National Institute of Allergy and Infectious Diseases grants to develop multi-specific antibodies targeting retinal neovascular diseases and pemphigus, respectively. The grants fall under the NIH's Extramural Research Programs supporting research in specialized areas.
SBA capabilities narrative
Provide services in recombinant antibody development, modification and production services
Quick answers
What is Abzyme Therapeutics LLC's UEI?
Abzyme Therapeutics LLC's Unique Entity ID (UEI) in SAM.gov is H2MLEFWV36N6.
What is Abzyme Therapeutics LLC's CAGE code?
Abzyme Therapeutics LLC's CAGE code is 62ES6.
What is Abzyme Therapeutics LLC's primary NAICS code?
Abzyme Therapeutics LLC's primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Abzyme Therapeutics LLC located?
Abzyme Therapeutics LLC's physical address in SAM.gov is 321 Jones Blvd #300, Pottstown, PA 19464, USA.
Is Abzyme Therapeutics LLC registered in SAM.gov?
Yes. Abzyme Therapeutics LLC's SAM.gov registration is active through January 2, 2027.
What is Abzyme Therapeutics LLC's most recent federal award?
Abzyme Therapeutics LLC's most recent federal grant award is Novel immune-escape uricase for treatment of hyperuricemia - abstract. High serum urate levels (hyperuricemia) and… (R43AI174703), from National Institute of Allergy and Infectious Diseases, on May 22, 2023.
On GovTribe
See Abzyme Therapeutics LLC's full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors